Form 8-K Enochian Biosciences For: Jul 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Enochian Biosciences (ENOB) Issues CEO Letter to Shareholders
July 6, 2022 9:14 AM EDTEnochian Biosciences (NASDAQ: ENOB) disclosed:
July 6, 2022
CEO Letter to Shareholders
After a rigorous review of internal data, Enochian Biosciences (the Company) is working aggressively to advance our HIV, cancer, and HBV pipelines towards potential studies in humans.
The foundation of the Company is built on innovative approaches to curing or putting into remission some of the worlds most devastating diseases using two primary product candidates: Hijack RNA, an approach that tricks viruses to induce death of the cells they infect to potentially limit illness and... More
